Evommune Inc., a clinical-stage biotechnology company focused on therapies for chronic inflammatory diseases, has announced a private placement of 4,494,279 shares of its common stock to select new and existing mutual funds and healthcare institutional investors at a price of $27.88 per share. The transaction is expected to raise approximately $125 million in gross proceeds, before transaction-related expenses, and is anticipated to close on or about February 17, 2026, subject to customary closing conditions. The securities offered in this private placement have not been registered under the Securities Act of 1933 and may not be sold in the United States without registration or an applicable exemption. Evommune plans to use the net proceeds to advance its clinical development programs and for general corporate purposes. Morgan Stanley & Co. LLC, Leerink Partners LLC, Evercore ISI, Cantor Fitzgerald & Co., and William Blair & Company, L.L.C. acted as placement agents, with Oppenheimer & Co. Inc. serving as capital markets advisor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212021278) on February 13, 2026, and is solely responsible for the information contained therein.